Revance Therapeutics reported $69.42M in Cash and Equivalent for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Aerie Pharmaceuticals AERI:US $ 39.44M 17M
ALKERMES ALKS:US $ 254.65M 27.91M
Bristol Myers Squibb BMY:US $ 10750M 1619M
Cara Therapeutics CARA:US $ 46.72M 25.36M
Coherus Biosciences CHRS:US $ 275.48M 50.2M
Eli Lilly And LLY:US $ 2622.9M 163.7M
Endo International Ordinary Shares ENDP:US $ 1191.57M 221.58M
Horizon Pharma HZNP:US $ 1892.56M 249.43M
Neurocrine Biosciences NBIX:US $ 163.3M 106.9M
Pacira Pharmaceuticals PCRX:US $ 122.06M 104.69M
Procter & Gamble PG:US $ 7214M 1312M
Revance Therapeutics RVNC:US $ 69.42M 128.94M
Supernus Pharmaceuticals SUPN:US $ 173.43M 57.71M
Teva Pharmaceutical Industries TEVA:US $ 2058M 117M